HIV-1 integrase inhibition: binding sites, structure activity relationships and future perspectives

Area of Science:

• Biochemistry
• Virology
• Drug Discovery

Background:

• The integrase enzyme is essential for the human immunodeficiency virus (HIV) life cycle, mediating viral DNA integration into the host genome.
• Despite numerous in vitro inhibitors, few have shown in vivo efficacy, highlighting challenges in targeting this enzyme.
• Integrase functions in the cytoplasm and nucleus, processing viral DNA and facilitating its insertion into host DNA.

Purpose of the Study:

• To review the current understanding of HIV integrase as a drug target.
• To explore the diverse binding sites and mechanisms of various integrase inhibitors.
• To discuss the challenges and progress in developing structure-activity relationships for integrase inhibitors.

Main Methods:

• Review of experimental and theoretical structural data on integrase.
• Analysis of chemical inhibitors targeting different stages of integrase function.
• Examination of cofactor dependency (manganese vs. magnesium ions) for inhibitor activity.

Main Results:

• Multiple binding targets for integrase inhibitors have been identified, including the enzyme itself, viral DNA, and the preintegration complex.
• Inhibitor efficacy varies based on cofactor presence and binding site.
• The complexity of inhibition mechanisms complicates the establishment of simple structure-activity relationships.

Conclusions:

• HIV integrase remains a promising but challenging drug target.
• Further structural and mechanistic studies are needed to overcome current limitations in developing effective integrase inhibitors.
• A deeper understanding of integrase-inhibitor interactions is crucial for advancing HIV therapeutics.